DarioHealth closed at $2.97 on Nov 4, down 1.00%, within 0.0% of its 52-week closing low. Volume of 58.7K shares was 0.91× its 20-day average (close to normal).
Split-adjusted performance: -50.7% over one month, -62.8% over six months.
In the quarter ended Jun 30, 2026, revenue was $5.18M, down 3.6% from a year earlier, with a net margin of -153.1%.
Short interest was 81.2K shares at the Oct 15 settlement (1.1% of float, 4.4 days to cover).
No reported quarters with price history yet.
Percentile among 110 companies (100 = best)
Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| DRIODarioHealth | $2.97 | −1.00% | −62.8% | −3.6% | −153.1% | 0.0 | $29.1M | |
| NEPHNephros | $3.25 | +0.31% | +0.9% | +36.2% | 19.9% | 20.3 | $35.3M | Compare |
| BEATHeartbeam | $0.4241 | −1.40% | −50.5% | — | — | — | $23.9M | Compare |
| NSPRInspireMD | $0.7810 | +18.71% | −32.7% | −0.4% | −808.8% | — | $36.6M | Compare |
| TELATELA Bio | $0.8378 | +4.46% | −15.4% | −4.5% | −58.4% | — | $37.8M | Compare |
| XTNTXtant Medical Holdings | $0.2960 | +6.47% | −48.7% | −35.0% | −40.9% | — | $41.5M | Compare |
| CVRXCVRx | $1.58 | +14.49% | −77.7% | +15.6% | −89.4% | — | $42.1M | Compare |
| ARAYAccuray Incorporated | $0.1491 | +3.97% | −68.7% | −20.9% | −1.9% | — | $17.8M | Compare |
| MDAISpectral AI | $1.53 | +2.00% | −31.1% | −30.4% | −118.5% | — | $49.2M | Compare |
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
